Skip to main content

Table 4 Main pathological characteristics of CD20-negative diffuse large B-cell lymphoma and CD20-positive diffuse large B-cell lymphoma patients

From: CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: A matched case-control analysis in a single institution

 

Total (tested)

CD20-negative DLBCL(n = 28)

CD20-positive DLBCL(n = 84)

P

IHC Subtypes

    

GCB

26(48.1%)

5(22.7%)

21(65.6%)

0.002

non-GCB

28(51.9%)

17(77.3%)

11(34.4%)

 

Ki-67

    

≥80%

30(42.3%)

17(70.8%)

13(27.7%)

<0.001

<80%

41(57.7%)

7(29.2%)

34(72.3%)

 

BCL-2

    

Positive

37(54.4%)

13(65%)

24(50%)

0.258

Negative

31(45.6%)

7(35%)

24(50%)

 

EBERs

    

Positive

2(6.9%)

1(4.8%)

1(12.5%)

0.483

Negative

27(93.1%)

20(95.2%)

7(87.5%)

 

CD30

    

Positive

14(19.4%)

9(36%)

5(10.6%)

0.023

Negative

58(80.6%)

16(64%)

42(89.4%)

 

ALK

    

Positive

7(20.6%)

5(20.8%)

2(20%)

1

Negative

27(79.4%)

19(79.2%)

8(80%)

 

Specified DLBCL

    

ALK-positive LBCL

5(4.5%)

5(17.9%)

0(0)

0.001

PBL

2(1.8%)

2(7.1%)

0(0)

0.061

PEL

0(0)

0(0)

0(0)

1

DLBCL with PD

4(3.6%)

3(10.7%)

1(1.2%)

0.078

  1. IHC, Immunohistochemical; GCB, germinal centre B-cell; DLBCL, diffuse large B-cell lymphoma; LBCL, large B-cell lymphoma; PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma; PD, plasmacytic differentiation.